Bespoke Extracts, Inc. Announces Financial Results for the Second Quarter ended June 30, 2025

Core Insights - Bespoke Extracts, Inc. reported a significant revenue increase of 48.4% in Q2 2025, reaching $390,553 compared to $263,159 in Q1 2025 and a 40.4% increase from $278,163 in Q2 2024 [2][4] - The company achieved a gross margin of 50.6%, which is an increase of 1,250 basis points year-over-year, reflecting improved operational efficiencies [2][4] - Despite the revenue growth, the company reported a GAAP net loss of $205,106 for Q2 2025, an improvement from a net loss of $260,895 in Q2 2024 [4][6] Financial Highlights - For the three months ended June 30, 2025: - Revenue: $390,553, up 40.4% year-over-year [4] - Gross Profit: $197,499, with a gross profit margin of 50.6% [3][4] - Net Loss: $205,106, resulting in a net loss per share of $0.02 [4][5] - For the six months ended June 30, 2025: - Revenue: $653,712, an increase of 21.4% compared to the same period in 2024 [4] - Gross Profit: $308,278, with a gross profit margin of 47.2% [5] - Net Loss: $465,627, with a net loss per share of $0.04 [5] Operational Highlights - The company produced a record number of over 177,000 pre-rolls in Q2 2025, driven by strong demand for its core Fresh Joints product line and new product lines like Doobskis and Dutch Blunts [6][7] - Continued improvements in manufacturing processes and cost efficiencies in raw materials, packaging, and labor contributed to the gross margin expansion [6][9] - The company is exploring expansion opportunities in other regulated cannabis markets, such as Massachusetts and New York [10] Future Outlook - Preliminary sales data for Q3 2025 indicates continued revenue growth, with projections between $425,000 and $450,000, representing a 53% to 62% increase over Q3 2024 [8] - The company expects further improvements in gross margins due to enhanced production efficiencies and cost management [9]